$IX生物制药 (42C.SG)$药品公司ix生物制药posted an S$830万 loss for the second half of the fiscal year ended June 2022, sinking deeper into the red from a S$540万 loss in H2 FY2021.
This came as the group recorded a negative fair value adjustment of S$310万 from its shares in Nasdaq-listed Seelos Therapeutics, which the group received during H1 to partially satisfy a US$900万 upfront fee under its Wafermine out-licensing agreement.
The depreciation of the Australian dollar against the Singapore dollar further dragged on the group's bottom line, contributing to a wider S$710,000 in currency exchange net losses compared to the previous year's S$359,000 loss.
$UtdHampshReitUSD (ODBU.SG)$:UNITED Hampshire US Reit(UHReit) has begun negotiations on refinancing options for its short-term liabilities maturing in March 2023, and is confident of a successful outcome, said the real estate investment trust's (Reit) manager in a bourse filing on Monday (Aug 22).
The announcement was in response to queries raised by the Singapore Exchange Securities Trading (SGX-ST) about UHReit's "significant liabilities of S$30920万 and cash and bank balance of only S$1260万".
In particular, SGX-St asked if the group's current assets are adequate to meet its short-term liabilities of S$10330万 and how it intends to fulfil its significant payment obligations in the next 12 months.